OPEN Foundation

Multipotent and Poly-therapeutic Fungal Alkaloids of Claviceps purpurea

Abstract

Claviceps are a group of phytopathogenic ascomycetes which includes around 50 known species. Claviceps purpureaClaviceps fusiformisClaviceps paspaliClaviceps africana, and Claviceps lutea are the most common and well-characterized fungi. Ergot alkaloids and other constituents derived from Claviceps are beneficial for various clinical applications in humans and animals. However, they also contain certain chemicals that are extremely addictive, abusive, and lethal. Ergot derivatives exhibit interesting pharmacokinetic and pharmacodynamic effects. Their pharmacodynamic actions are attributed to their agonistic, partial agonistic, and antagonistic effects on different receptors pertaining to the monoaminergic neurotransmitters. Due to their binding (with or without intrinsic effects) ability on the receptors, they induce numerous pharmacological effects which have potential medical values. Methysergide, ergotamine, dihydroergotamine, ergometrine (ergonovine), pergolide, ergoloid mesylates, and bromocriptine are the most popular ergot-based drugs used globally for treating numerous diseases. These drugs have been used to treat inflammatory-, infectious-, neurological-, cardiovascular-, gastrointestinal-, endocrinological-, sexual-, and urological-related pathologies. Hence, they are considered as a multipotent and poly-therapeutic fungus.

Majrashi, M., Ramesh, S., Deruiter, J., Mulabagal, V., Pondugula, S., Clark, R., & Dhanasekaran, M. (2017). Multipotent and Poly-therapeutic Fungal Alkaloids of Claviceps purpurea. In Medicinal Plants and Fungi: Recent Advances in Research and Development (pp. 229-252). Springer, Singapore. 10.1007/978-981-10-5978-0_8
Link to full text

OPEN Foundation

Share This Post

get the latest

The OPEN Minded Newsletter keeps you informed about the latest psychedelic research & news, articles, exclusive events, job opportunities, programmes, and free resources!

By clicking SUBSCRIBE, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.

interested in becoming a trained psychedelic-assisted therapist?

Q&A with Rachel Harris: Wisdom from the Psychedelic Underground - Online Event - Oct 16th